Phase 2 Clinical Trial of High-Dose Gemcitabine/Busulfan/Melphalan for Autologous Stem-Cell Transplantation in Relapsed/Refractory Myeloma: Matched-Pair Comparison with Melphalan

BACKGROUND: High-dose melphalan is of limited benefit as autologous stem-cell transplantation (ASCT) regimen for relapsed/refractory myeloma. Its poor results in this setting prompted us to study a new high-dose combination of infusional gemcitabine/busulfan/melphalan (Gem/Bu/Mel). METHODS: We condu...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Lancet Haematol
Hlavní autoři: Nieto, Yago, Valdez, Benigno C, Pingali, Sai R, Bassett, Roland, Delgado, Ruby, Nguyen, John, Shah, Nina, Popat, Uday, Jones, Roy B, Andersson, Borje S, Gulbis, Alison, Ahmed, Sairah, Bashir, Qaiser, Parmar, Simrit, Patel, Krina, Myers, Alan, Rondon, Gabriela, Orlowski, Robert Z, Champlin, Richard, Qazilbash, Muzaffar
Médium: Artigo
Jazyk:Inglês
Vydáno: 2017
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5844223/
https://ncbi.nlm.nih.gov/pubmed/28522110
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2352-3026(17)30080-7
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky